中文摘要：

目的：探讨纳米金（gold nanoparticles，GNPs）对人肝癌阿霉素（adriamycin，ADM）耐药细胞株HepG2／ADM的阿霉素耐药性的逆转作用及其可能机制。方法：MTT比色法检测GNPs对人肝癌细胞株HepG2及其耐药细胞株HepG2／ADM对不同浓度 ADM 耐药性的影响；流式细胞术检测 GNPs 处理后 ADM （2 mg／L ）对HepG2／ADM细胞凋亡的影响；紫外分光光度计检测GNPs处理后HepG2／ADM细胞内ADM的药物浓度；谷胱甘肽（ GSH）检测试剂盒（ DTNB法）检测GNPs处理后HepG2／ADM细胞GSH的含量。结果：GNPs处理前HepG2和HepG2／ADM细胞对不同浓度ADM的半数抑制浓度分别为：（9．16±2．03）mg／L、（29．46±1．73）mg／L，耐药倍数为3．22；GNPs处理后HepG2／ADM 细胞对不同浓度ADM的半数抑制浓度为（15．18±0．85）mg／L，逆转指数为1．95。GNPs＋ADM组HepG2／ADM的细胞凋亡率明显高于单独ADM组（P＜0．05）。 HepG2／ADM组细胞内的ADM含量低于HepG2组细胞内的ADM含量（ P＜0．01）；GNPs处理后HepG2／ADM细胞内的ADM含量较处理前明显增加（P＜0．01）。 HepG2／ADM组细胞内GSH含量高于HepG2组（P＜0．01）；GNPs处理后HepG2／ADM细胞内的GSH含量较处理前明显降低（ P＜0．05）。结论：纳米金具有逆转耐药肝癌细胞对阿霉素耐药性的作用，并且可以降低细胞内GSH含量及增加胞内化疗药物浓度。

英文摘要：

AIM：To investigate whether gold nanoparticles （GNPs） reverses adriamycin （ADM）, resistance of human hepatocellular carcinoma drug-resistant cell line HepG2/ADM and to explore the potential mechanism.METH-ODS：The sensitivities of HepG2 cells and HepG2/ADM cells to ADM were tested by MTT assay before and after GNPs pretreatment.The apoptotic rate was examined by flow cytometry.The concentration of ADM in HepG2/ADM or HepG2 cells was determined by ultraviolet-visible spectrophotometer .The content of glutathione （ GSH ） in HepG2/ADM or HepG2 cells by DTNB method.RESULTS：The half maximal inhibitory concentrations （ IC50 ） of ADM for HepG2/ADM cells were（29.46 ±1.73） mg/L and （15.18 ±0.85） mg/L before and after GNPs pretreatment,respectively.The IC50 of ADM for HepG2 cells was （9.16 ±2.03） mg/L before pretreatment.The apoptotic rate in GNPs＋ADM group was higher than that in ADM group （ P〈0.05 ） .The concentration of ADM in HepG2/ADM group was lower than that in HepG2 group （P〈0.01）.After GNPs pretreatment, the concentration of ADM in HepG2/ADM cells was higher than that before pretreatment.The content of GSH in HepG2/ADM group was higher than that in HepG2 group （P〈0.01）.After GNPs pretreatment, the content of GSH in the HepG2/ADM cells was lower than that before pretreatment.CONCLUSION：Gold nanoparticles can reverse ADM resistance of human hepatocellular carcinoma drug-resistant cell line HepG2/ADM, 〈br〉 reduce the content of GSH and increase the concentration of ADM in HepG2/ADM cells.